Skin Neoplasms Clinical Trial
Official title:
Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection
Verified date | June 2018 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot randomized controlled trial of an Internet-based skin cancer prevention intervention as compared to a standard of care control in 80 non-Hispanic white females ages 20-30.
Status | Completed |
Enrollment | 80 |
Est. completion date | February 27, 2018 |
Est. primary completion date | February 27, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Tanned indoors in past 12 months - Able to communicate well in English - Reliable Internet access Exclusion Criteria: - History of skin cancer (self-report) |
Country | Name | City | State |
---|---|---|---|
United States | Yale School of Public Health | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | American Cancer Society, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intention to indoor tan in next year | Indoor tanning intentions are measured on a scale that ranges from 1 (definitely do not intend to indoor tan) to 7 (definitely do intend to indoor tan). | Baseline | |
Primary | Intention to indoor tan in next year | Indoor tanning intentions are measured on a scale that ranges from 1 (definitely do not intend to indoor tan) to 7 (definitely do intend to indoor tan). | 12 Weeks First Follow-up | |
Primary | Intention to indoor tan in next year | Indoor tanning intentions are measured on a scale that ranges from 1 (definitely do not intend to indoor tan) to 7 (definitely do intend to indoor tan). | 24 Weeks Second Follow-up | |
Primary | Number of indoor tanning sessions in the previous 3 months | Self-report measure of number of times indoor tanned, reported retrospectively for the preceding 3 months. | 12 weeks preceding baseline | |
Primary | Number of indoor tanning sessions in the previous 3 months | Self-report measure of number of times indoor tanned, reported retrospectively for the preceding 3 months. | baseline to 12 Weeks (First Follow-up) | |
Primary | Number of indoor tanning sessions in the previous 3 months | Self-report measure of number of times indoor tanned, reported retrospectively for the preceding 3 months. | From 12 Weeks (first Follow-up) to 24 Weeks (Second Follow-up) | |
Secondary | Intention to sunbathe outdoors in the next year | Sunbathing intentions are measured on a scale that ranges from 1 (definitely do not intend to indoor tan) to 7 (definitely do intend to indoor tan). | Baseline | |
Secondary | Intention to sunbathe outdoors in the next year | Sunbathing intentions are measured on a scale that ranges from 1 (definitely do not intend to indoor tan) to 7 (definitely do intend to indoor tan). | 12 weeks First Follow-up | |
Secondary | Intention to sunbathe outdoors in the next year | Sunbathing intentions are measured on a scale that ranges from 1 (definitely do not intend to indoor tan) to 7 (definitely do intend to indoor tan). | 24 weeks Second Follow-up | |
Secondary | Number of outdoor sunbathing sessions in the previous 3 months | Self-report measure of number of times sunbathed, reported retrospectively for the preceding 3 months. | 12 weeks preceding baseline | |
Secondary | Number of outdoor sunbathing sessions in the previous 3 months | Self-report measure of number of times sunbathed, reported retrospectively for the preceding 3 months. | baseline to 12 Weeks (First Follow-up) | |
Secondary | Number of outdoor sunbathing sessions in the previous 3 months | Self-report measure of number of times sunbathed, reported retrospectively for the preceding 3 months. | From 12 Weeks (first Follow-up) to 24 Weeks (Second Follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00027586 -
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Not yet recruiting |
NCT02230462 -
Patient Satisfaction After Facial Reconstruction
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Completed |
NCT00224744 -
Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage
|
Phase 3 | |
Terminated |
NCT00865878 -
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
|
Phase 2 | |
Not yet recruiting |
NCT05359419 -
Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities
|
Phase 4 | |
Active, not recruiting |
NCT00001813 -
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
|
||
Completed |
NCT02046811 -
Reducing Skin Cancer Risk in Childhood Cancer Survivors
|
N/A | |
Completed |
NCT02147080 -
A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults
|
N/A | |
Completed |
NCT00007631 -
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
|
Phase 3 | |
Completed |
NCT00847912 -
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
|
Phase 4 | |
Recruiting |
NCT02836548 -
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT01482104 -
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
|
N/A | |
Enrolling by invitation |
NCT04630886 -
Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery
|
Early Phase 1 | |
Completed |
NCT03012581 -
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
|
Phase 2 | |
Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
Not yet recruiting |
NCT02408835 -
Negative Pressure Wound Therapy in Groin Dissection
|
N/A | |
Completed |
NCT00204789 -
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
|
Phase 2 | |
Completed |
NCT02310503 -
Spanish Registry of Mohs Surgery
|
||
Active, not recruiting |
NCT04267861 -
M7824 Related Adverse Effects in Adults With Cancer
|